News Vertex hit by phase 3 cystic fibrosis failure Company looks to other CF sub-groups to yield success
News Vertex seeks deal after NICE rejects CF drug Orkambi Company in talks with NICE over patient access scheme.
News Biogen signs $1bn gene therapy deal; CF trial shows promise Biogen following move into regenerative medicine
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
